pre-IPO PHARMA

COMPANY OVERVIEW

Celularity is a clinical-stage cell therapeutics company delivering transformative allogeneic cellular therapies, engineered from the postpartum human placenta, in cancer immunotherapy and functional regeneration. Some of our placenta-derived allogeneic cell therapy products aim to augment immunity by harnessing a patient’s own immune system to combat disease. Our other products seek to augment longevity by targeting organ and tissue repair and functional regeneration. With this approach, our ambition is to augment human immunity and longevity, and to improve the human health span.


LOCATION

  • Warren, NJ, USA

  • THERAPEUTIC AREAS

  • Hematology
  • Oncology
  • Regenerative Medicine

  • WEBSITE

    https://www.celularity.com


    CAREER WEBSITE

    https://careers-celularity.icims.com/jobs/


    SOCIAL MEDIA


    INVESTORS

    celgene dreyfus-family-office genting-group heritage-group human-longevity section-32 sorrento-therapeutics united-therapeutics


    PRESS RELEASES


    May 20, 2021

    Celularity Appoints Bradley Glover, Ph.D. as Executive Vice President and Chief Technology Officer


    May 5, 2021

    Celularity Enters into Multi-Year Strategic Partnership with Palantir Technologies


    Mar 18, 2021

    Celularity Announces Fast Track Designation by the FDA for its Natural Killer Cell Therapy CYNK-001 in the Treatment of Recurrent Glioblastoma Multiforme


    Mar 9, 2021

    Celularity to Present at H.C. Wainwright Global Life Sciences Conference


    Apr 2, 2020

    SORRENTO TO PROVIDE MANUFACTURING SUPPORT TO CELULARITY AS CYNK-001 NK CELL TRIAL FOR COVID-19 BEGINS ENROLLING PATIENTS


    For More Press Releases


    Google Analytics Alternative